BR0210547A - Método e material para tratar doenças imunes - Google Patents

Método e material para tratar doenças imunes

Info

Publication number
BR0210547A
BR0210547A BR0210547-0A BR0210547A BR0210547A BR 0210547 A BR0210547 A BR 0210547A BR 0210547 A BR0210547 A BR 0210547A BR 0210547 A BR0210547 A BR 0210547A
Authority
BR
Brazil
Prior art keywords
galectin
backbone
organism
binds
therapeutic
Prior art date
Application number
BR0210547-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Yang Chang
Vodek Sasek
Original Assignee
Glycogenesys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycogenesys Inc filed Critical Glycogenesys Inc
Publication of BR0210547A publication Critical patent/BR0210547A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/732—Pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
BR0210547-0A 2001-06-22 2002-06-21 Método e material para tratar doenças imunes BR0210547A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30036001P 2001-06-22 2001-06-22
US10/176,022 US20030004132A1 (en) 2001-06-22 2002-06-20 Method and material for treating immune diseases
PCT/US2002/019886 WO2003000195A2 (en) 2001-06-22 2002-06-21 Method and material for treating immune diseases

Publications (1)

Publication Number Publication Date
BR0210547A true BR0210547A (pt) 2004-05-25

Family

ID=26871794

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0210547-0A BR0210547A (pt) 2001-06-22 2002-06-21 Método e material para tratar doenças imunes

Country Status (8)

Country Link
US (1) US20030004132A1 (https=)
EP (1) EP1408989A2 (https=)
JP (1) JP2004536825A (https=)
CN (1) CN100558368C (https=)
BR (1) BR0210547A (https=)
CA (1) CA2451885A1 (https=)
IL (1) IL159462A0 (https=)
WO (1) WO2003000195A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040223971A1 (en) * 2003-04-07 2004-11-11 Glycogenesys, Inc. Composition and uses of galectin antagonists
WO2004091634A1 (en) 2003-04-07 2004-10-28 Glycogenesys, Inc. Composition and uses of galectin antagonists
WO2005058352A2 (en) * 2003-12-17 2005-06-30 Entelos, Inc. Treatment of rheumatoid arthritis with galectin-3 antagonists
WO2005095463A1 (en) 2004-03-26 2005-10-13 Glycogenesys, Inc. Modified pectins, compositions and methods related thereto
ES2750126T3 (es) 2011-03-17 2020-03-25 Critical Care Diagnostics Inc Procedimientos de predicción del riesgo de un resultado clínico adverso
AU2012363033B2 (en) 2011-12-28 2016-06-02 Galectin Therapeutics, Inc. Composition of novel carbohydrate drug for treatment of human diseases
ES2848538T3 (es) * 2012-06-06 2021-08-10 Galectin Therapeutics Inc Composiciones de galacto-ramnogalacturonato para el tratamiento de enfermedades asociadas con elevada óxido nítrico sintasa inducible
DK2900061T3 (da) 2012-09-17 2020-03-02 Galectin Therapeutics Inc Fremgangsmåde til forstærkning af specifikke immunterapier ved cancerbehandling
US8828971B2 (en) 2012-10-10 2014-09-09 Galectin Therapeutics, Inc. Galactose-pronged carbohydrate compounds for the treatment of diabetic nephropathy and associated disorders
US9907814B2 (en) 2012-12-20 2018-03-06 Henry Ford Health System Method for treating diastolic heart failure by inhibiting galectin-3
US12390486B2 (en) 2012-12-20 2025-08-19 Henry Ford Health System Method for treating diastolic heart failure by inhibiting galectin-3
US9339515B2 (en) 2013-02-20 2016-05-17 Galectin Therapeutics, Inc. Method for treatment of pulmonary fibrosis
CA3088736A1 (en) * 2018-01-21 2019-07-25 Rensselaer Polytechnic Institute Method of treating galectin-3 dependent disorders
US20210138080A1 (en) 2018-06-29 2021-05-13 Glykos Biomedical Oy Conjugates
US20230038373A1 (en) 2019-12-18 2023-02-09 Glykos Biomedical Oy Stabile conjugate

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5490991A (en) * 1986-07-03 1996-02-13 Advanced Magnetics, Inc. Directed delivery of radioprotectants using a receptor specific carrier
DE69118141T2 (de) * 1990-06-27 1996-09-19 Dainippon Ink & Chemicals Alkyliertes oligosaccharid und acetylderivate davon
US5498702A (en) * 1993-12-16 1996-03-12 California Natural Products Treated pectinic acid process and product
US5834442A (en) * 1994-07-07 1998-11-10 Barbara Ann Karmanos Cancer Institute Method for inhibiting cancer metastasis by oral administration of soluble modified citrus pectin
US5831052A (en) * 1997-05-07 1998-11-03 Incyte Pharmaceuticals, Inc. New human translocation associated protein
US6258383B1 (en) * 1998-08-14 2001-07-10 Lactoferrin Products Company Dietary supplement combining colostrum and lactoferrin in a mucosal delivery format
US6500807B1 (en) * 1999-02-02 2002-12-31 Safescience, Inc. Modified pectin and nucleic acid composition
US6680306B2 (en) * 2001-06-21 2004-01-20 Glycogenesys, Inc. Method for enhancing the effectiveness of cancer therapies

Also Published As

Publication number Publication date
US20030004132A1 (en) 2003-01-02
JP2004536825A (ja) 2004-12-09
CA2451885A1 (en) 2003-01-03
IL159462A0 (en) 2004-06-01
CN1543352A (zh) 2004-11-03
WO2003000195A3 (en) 2003-03-20
CN100558368C (zh) 2009-11-11
WO2003000195A2 (en) 2003-01-03
EP1408989A2 (en) 2004-04-21

Similar Documents

Publication Publication Date Title
BR0210547A (pt) Método e material para tratar doenças imunes
BR9807083A (pt) Antagonistas ao receptor de il-8
BR0009520A (pt) Composto, método para sintetizar o mesmo, composição, metódos para o tratramento ou prevenção, em um paciente, de doença cardiovascular, dislipidemia, dislipoproteinemia, distúrbio de metabolismo de glucose, doença de alzheimer, sìndrome x ou sìndrome metabólica, septicemia, distúrbio trombótico, distúrbio associado com receptor ativado por proliferador de peroxissoma, obesidade, pancreatite, hipertensão, doença renal, câncer, inflamação, impotência, para reduzir o teor de gordura de carne de gado bovino, e, para reduzir o teor de colesterol de ovos de aves
BR9909908A (pt) Derivados de ácidos graxos de ácidos biliares e derivados de ácidos biliares
BR0013814A (pt) Métodos de tratamentos de um paciente humano suscetìvel a ou diagnosticado com uma doença com anticorpos anti-erbb2, artigos industrializados, métodos de tratamentos de câncer em pacientes humanos e usos do anticorpo anti-erbb2
CA2001754A1 (en) Glucan dietary additives
BR9810944A (pt) Controle de sìndrome de intestino acìdico
ATE247974T1 (de) Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen
BR9607839A (pt) Derivado de peptídeo composição para o tratamento de distúrbios trombóticos e processo para o tratamento ou profilaxia de doenças vasculares relacionadas com a trombose
BR9916879A (pt) Composição e método para tratamento do câncer utilizando óleos essenciais vegetais naturais
WO1997017446A3 (en) HUMANIZED ANTIBODIES TO HUMAN gp39, COMPOSITIONS CONTAINING AND THERAPEUTIC USE THEREOF
BR0010669A (pt) Método para o tratamento de fibrose usando um antagonista da subunidade alfa-4 da integrina
BR0007556A (pt) Antagonistas de tweak e de receptor de tweak e uso dos mesmos para tratar distúrbios imunológicos
BR0212907A (pt) Métodos para tratamento ou prevenção de inflamação vascular usando inibidor(es) da absorção de esteróis
BR9809951A (pt) Método para tratamento da obesidade
EP1242115A4 (en) CHEMICALLY PROGRAMMABLE IMMUNITY
CO5130025A1 (es) METODO PARA TRATAR ATEROESCLEROSIS EMPLEANDO UN INHIBIDOR DE ap2 Y COMBINACION
EP0401903A3 (en) The use of vanilloids for the treatment of respiratory diseases or disorders
CY1107436T1 (el) Χρηση των αναστολεων της ενδοτοξινης για την θεραπεια της καχεξιας
DK0858504T3 (da) Diagnostiske midler mod og behandlinger af periodontale sygdomme
BR9805318A (pt) Método para tratamento de infecções dos olhos com azitromicina.
Azofeifa et al. Ability of fucoidan to prevent muscle necrosis induced by snake venom myotoxins: Comparison of high-and low-molecular weight fractions
RU2223782C2 (ru) Средство для лечения патологического костного метаболизма
BR9807085A (pt) Antagonistas de receptor de il-8
WO2002020619A3 (en) HUMAN ANTIBODIES AGAINST PSEUDOMONAS AERUGINOSA LPS DERIVED FROM TRANSGENIC XENOMOUSE$m(3)

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A,6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2029 DE 24/11/2009.